Asset Management One Co. Ltd. Sells 26,782 Shares of Pfizer Inc. $PFE

Key Points

• Asset Management One Co. Ltd. has decreased its holdings in Pfizer Inc. by 1.0%, selling 26,782 shares, leaving them with a total of 2,529,246 shares valued at approximately $61.3 million.
• Pfizer's quarterly earnings exceeded analysts' expectations, reporting an EPS of $0.78 and revenues of $14.65 billion, a significant increase from the prior year.
• The company recently announced a $0.43 quarterly dividend to shareholders, with a yield of 7.0% and an upcoming ex-dividend date of November 7th.

Asset Management One Co. Ltd. lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 1.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 2,529,246 shares of the biopharmaceutical company's stock after selling 26,782 shares during the period. Asset Management One Co. Ltd.'s holdings in Pfizer were worth $61,309,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. acquired a new position in Pfizer in the 1st quarter valued at $28,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the first quarter worth about $28,000. Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. Finally, Horizon Financial Services LLC acquired a new position in shares of Pfizer during the 1st quarter valued at about $35,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

NYSE:PFE opened at $24.68 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.17. The firm has a market cap of $140.29 billion, a price-to-earnings ratio of 13.13, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company's 50-day moving average is $24.87 and its two-hundred day moving average is $24.15. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 EPS. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer's dividend payout ratio is presently 91.49%.

Analysts Set New Price Targets

A number of research firms have commented on PFE. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. UBS Group restated a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a report on Friday, October 10th. Finally, Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.